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Introduction
Osteosarcoma (OS) is the most common primary malignant bone tumor in both children and young adults with a peak of incidence at 18 years (1, 2) . The tumor generally develops on the average part of the long bones (femur and tibia). Current therapeutic protocols combine neoadjuvant poly-chemotherapy with conservative surgery. The long-term survival rate is 60% to 75% at 5 years for patients with localized tumor but is drastically lowered to 20% if pulmonary metastases are detected at diagnosis. To significantly improve survival in children with OS, new therapeutic strategies targeting the molecular basis of OS are required.
Heat shock protein-90 (HSP90) is an ATPase-dependent molecular chaperone that is abundantly and ubiquitously expressed in normal cells (3) . HSP90 plays a pivotal role in assisting correct folding and functionality of its client proteins in cells, protecting them from aggregation (4) . Tumor cells are constantly stressed (aneuploidy, hypoxia, oncoproteins, treatment…) and consequently exhibit higher HSP90 activity and expression compared with normal cells (4, 5) . Thus, HSP90 appears as a therapeutic target of relevance in OS since it acts as "hyper-node" to control multiple survival pathways involved in tumor progression, migration and invasion. Many HSP90 inhibitors targeting the ATPase pocket have been developed.
Geldanamycin derivatives (e.g. 17-AAG) were the first proof-of-concept showing HSP90 as a druggable target for cancer therapy. However, 17-AAG contains a benzoquinone moiety that can cause liver toxicity (6) , and is poorly soluble leading to formulation challenges and additional toxicities, that have limited its clinical development. Synthetic HSP90 inhibitors with improved pharmacological properties and safety profiles might overcome some of the constraints for clinical development of the first generation of HSP90 inhibitors. For example, other novel HSP90 inhibitors (PU-H71, NVP-AUY922…) were described to induce apoptosis in preclinical studies of various cancers (4, (7) (8) (9) , including primary bone tumors (10, 11) , and are currently in clinical trials in various cancers. However, little is known regarding the potential activity of HSP90 inhibitors in sarcomas. PF4942847, an orally nonquinone-based HSP90 inhibitor that competitively binds to the N-terminal adenosine trisphosphate-binding site of HSP90 (12) , and described as extremely potent in triple-negative breast cancer (12) , could be a promising therapeutic approach for patients with OS.
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Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR- There are however, some limitations. Bone microenvironment plays a major role in OS tumor progression by the establishment of a vicious cycle between tumor proliferation and bone resorption (1) . In this context, the role of HSP90 inhibition is controversial. Indeed, conflicting studies suggest that in one hand HSP90 inhibition may inhibit both primary tumor growth and bone tumor metastasis (13) , while in the other hand several studies have reported that HSP90 inhibition using 17-AAG promotes tumor growth in bone by inducing osteoclast differentiation and activation (14, 15) , raising concerns as for patients with tumor-associated bone lesions. 17-AAG was reported to potentiate tumor growth in bone by inducing osteoclastogenesis in bone metastasis models (14, 15) . In this study, we show that 17-AAG, but not PF4942847, induces osteoclast formation. Thus, combining PF4942847 with anti-osteoclastic drugs could be an alternative therapeutic strategy. Among these drugs, zoledronic acid (ZOL) is the second generation of nitrogen-containing bisphosphonates (N-BPs), that are stable synthetic analogues of endogenous pyrophosphate (PPi) (16) . ZOL is one of the most potent inhibitors of bone resorption in clinical use inducing osteoclast apoptosis by inhibiting enzymes of the mevalonate pathway (17, 18). Moreover, ZOL also directly inhibits proliferation and induces apoptosis of tumor cells, thus delaying tumor growth in OS models (19, 20) . Consequently, in the vicious cycle context, combining ZOL with PF4942847 would represent an exciting therapeutic alternative to treat OS by targeting both tumor cells and bone microenvironment.
In the present study, we elucidated the mechanistic and anti-cancer activity of PF4942847, as a single agent or in combination with ZOL, both in vitro and in vivo, in a panel of human osteosarcoma cell lines and xenograft models. We performed our experiments on tumor growth, metastatic dissemination and tumor-associated bone lesions to determine its potential clinical utility.
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Materials and Methods:

Tumor cell lines and reagents:
The human osteosarcoma cancer cell lines HOS-MNNG (CRL-1547), KHOS (CRL-1544) MG63, U2OS, SJSA1, G292, Cal72, 143B and SaOS2, were purchased from the American Type Culture Collection and maintained in DMEM (Invitrogen-Life Technologies, Inc.) supplemented with 5% fetal bovine serum (FBS) and 2mmol/L L-glutamine. All cell lines were cultured in a humidified 5% CO 2 /air atmosphere at 37 o C. All cell lines were passaged for less than 3 months after resurrection and were authenticated by short tandem repeat (STR) profiling.
Therapeutic agents
HSP90 inhibitor, PF4942847, orally bioavailable was kindly provided from Pfizer (La Jolla, CA) and used for in vitro and in vivo studies. This compound is a synthetic small molecule inhibitor that bind the N-terminal adenosine triphosphate binding site of HSP90. For the in vitro studies, PF4942847 was dissolved in dimethyl sulfoxide (DMSO) at 10 mM stock solution and stored at -20 o C. For the in vivo studies, PF4942847 was dissolved in 40% PEG + 60% PBS (at 15 mg/ml and stored at 4 o C).
17-allylamino-17-demethoxygeldanamycin (17-AAG) was purchased from Sigma-Aldrich and dissolved in DMSO at 10mM stock solutions and stored at -20 o C.
ZOL, 1-hydroxy-2-(1H-imidazole-1-yl) ethylidene-bisphosphonic acid supplied as the disodium salt by Novartis Pharma AG, was dissolved in PBS at 10mM stock solution and stored at -20°C.
Cell proliferation assay, pulse exposure and apoptosis assays:
Human OS cells lines were treated with PF4942847 at indicated concentration and time.
After time course exposure, cell growth was measured using the crystal violet assay.
Detection and quantitation of apoptotic cells were done by flow-cytometry and western blotting analysis. Each assay was repeated in triplicate.
For pulse-exposure experiments, HOS-MNNG and U2OS cells were exposed to 100nM PF4942847. After 2, 6, 16 and 24h of exposure, cells were washed extensively with PBS and returned to PF4942847-free culture. Cell growth was checked by crystal violet assay at 24, 48, 72 and 96 h.
Research. The combination index (CI) was evaluated using CalcuSyn dose effect analysis software (Biosoft, Cambridge, UK). This method, based on the multiple drug effect equation of ChouTalalay (21).
Caspase 3 activity was assessed two days after treatment using the Fluorometric CaspACE Assay System, (Promega, Madison, USA) as already described in Lamoureux et al. (22) .
Cell cycle analysis
OS cells were treated with 100 or 200nM PF4942847 for 48 hrs, trypsinized, washed twice and incubated in PBS containing 0.12% Triton X-100, 0.12mM EDTA and 100μg/ml ribonuclease A. 50μg/ml propidium iodide was then added to each sample for 20min at 4°C.
Cell cycle distribution was analyzed by flow cytometry (Beckman Coulter Epics Elite, Beckman, Miami, FL), based on 2N and 4N DNA content. Each assay was done in triplicate.
Quantitative Reverse Transcription-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, Inc.). Realtime monitoring of PCR amplification of cDNA was performed using DNA primers (supplemental table S1) on CFX96 Detector System (Bio-Rad) with SYBR PCR Master Mix (Bio-Rad). Target gene expression was normalized to GAPDH level in respective samples as an internal standard, and the comparative cycle threshold (Ct) method was used to calculated relative quantification of target mRNAs. Each assay was performed in triplicate.
Western-blotting analysis:
Samples containing equal amounts of protein from lysates of cultured OS cells underwent electrophoresis on SDS-polyacrylamide gel and were transferred to nitrocellulose filters blocked in PBS-BSA 3%-Tween 0.05%. And then, blots were probed overnight at 4°C with primary antibodies (supplementary Table S2 ). After incubation, the filters were washed in PBS containing 0.1% Tween. Filters were then probed with the secondary antibody coupled to horseradish peroxidase. Antibody binding was visualized with the enhanced chemiluminescence system (Roche Molecular Biomedicals).
Research. per ml) were re-suspended in DMEM containing 0.1% FBS, and 300 μl of this cell suspension was loaded into each insert (upper chamber). The chemo-attractant (10% FBS) was placed in the lower chamber (750 μl per well). The plates were incubated for 8h at 37°C.
Then, the inserts were carefully collected, the non-migrating cells were removed, and the migrating cells on the under-surface of the inserts were fixed and stained with crystal violet and, then counted by bright-field microscopy.
Zymography
The presence of MMP-2 and MMP-9 in serum-free conditioned media was analyzed by zymography in 10% sodium dodecyl sulfate-polyacrylamide gels containing 1 mg/mL gelatin (Sigma-Aldrich). After removal of sodium dodecyl sulfate with Triton X-100, neutral protease activity was revealed by incubation of the gels for 48hours at 37°C in 50mM Tris buffer (pH 7.4) containing 2mM CaCI2, followed by staining in 0.05% Coomassie blue in an aqueous solution containing 20% isopropanol and 10% acetic acid. Pictures were taken using G-Box (Syngene, Cambridge, UK). 
Animal Treatment
MicroCT analysis.
Tibias were scanned using high-resolution microcomputed tomography (Skyscan 1076, Kontich, Belgium) at 50kV and 200mA using a 0.5mm aluminium filter and a detection pixel size of 9mm. Images were captured every 0.6° through 180° rotation, and analysed using Skyscan software. Trabecular structures positioned 0.2mm below the growth plate were quantified over a length of 1mm. BV/TV and Tb.N of trabecular bone as well as BS and BV of cortical bone were determined.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded 3µm sections of tumor samples. Immunostaining for Ki67, cleaved-caspase-3, CD146 were conducted using a primary antibody anti-human Ki67 softwares. All analyses were assessed by light microscopy using a DMRXA microscope (Leica). All comparisons were made at x200 magnifications.
Osteoclast differentiation assays
Osteoclasts were generated from human CD14+ monocytes of different donors. Purified CD14+ cells were cultured in α-MEM (Invitrogen Life Technologies) with 10% FBS and 25ng/mL human macrophage colony stimulating factor (hM-CSF; R&D Systems). After 4 days, 100ng/mL hRANKL +/-100nM 17-AAG or PF4942847 were added. Multinucleated cells with more than three nuclei were counted after Tartrate-Resistant Acid Phosphatase (TRAP) staining (Sigma, France). All experiments were performed at least three times.
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Statistical analysis
All in vitro data were assessed using the Student t test and Mann-Whitney test. Tumor volumes of mice were compared using Kruskal-Wallis test. Overall survival was analyzed using Kaplan-Meier curves and statistical significance between the groups was assessed with the log-rank test (Graphpad Prism). Levels of statistical significance were set at P<0.05.
Research. Results:
PF4942847 inhibits osteosarcoma cell proliferation
Before planning any therapeutic strategy targeting HSP90, we evaluated the mRNA expression levels of HSP90 in human OS patient samples. Compared to normal osteoblast cells, all patients overexpressed HSP90, making all those OS patients good candidates for HSP90 inhibition as an alternative therapeutic strategy in OS treatment (Supp. Figure 1 ).
We first assessed the effects of inhibitors of HSP90, namely PF4942847 and the well-known 17-AAG, on cell growth in nine genetically defined human OS cell lines. In all cell lines, PF4942847 inhibited cell growth in a dose-dependent manner, with IC 50 values ranging from 13.48 to 97.31nM ( Fig 1A) . Moreover, PF4942847 was 2.5 to 27 fold more potent than 17-AAG ( Fig 1A) . Then, we chose the most PF4942847-sensitive HOS-MNNG, and the low/moderate sensitive U2OS cell lines for further in vitro investigations. Pulse exposure of these cell lines showed that 16h of drug exposition were sufficient to induce growth inhibition at 48h, 72h and 96h of culture, while 2 and 6 hours of drug exposition had no significant effect on cell proliferation (Fig. 1B, left panel) . Moreover, colony formation assays after 48h of PF4942847 treatment showed that inhibition of HSP90 significantly reduced the ability of tumor cells to form colony (Fig 1B, right panel) .
PF4942847 induces apoptosis and down-regulates HSP90 client proteins in osteosarcoma tumor cell lines
We next assessed the effects of HSP90 inhibition on OS cancer cell apoptosis using flowcytometric, western blot analyses and enzymatic caspase-3/7 activity. The fraction of cells undergoing apoptosis (subG1 fraction) significantly increased in a dose-dependent manner with PF4942847 compared to control, in both HOS-MNNG and U2OS cells (respectively 88% and 34% vs 3% and 6.1% in control; Fig 1C, upper panel) . Furthermore, PF4942847 induced apoptosis as shown by increasing caspase-3 activation in a dose-dependent manner in both cells lines ( Fig 1C, bottom panel) . These results were confirmed by western-blot analysis showing an increase of both cleaved-caspase-3 and cleaved-PARP expression in tumor cells (Fig 1D) . Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR- Because inhibition of HSP90 causes proteasomal degradation of a subset of cellular proteins, we next investigated the effect of PF4942847 on HSP90-client proteins and HSP70.
Expression of HSP70, a typical marker of HSP90 inhibition (23, 24), was increased by PF4942847 in a dose-dependent manner in OS cells at both mRNA and protein levels ( Fig   1D and Supp. Fig.2A ). PF4942847 also decreased protein levels of client proteins (Fig 1D) , while mRNA levels did not change (Supp. Fig.2A ), suggesting a regulation at the protein level. We then checked whether PF4942847 induced proteosomal degradation of client proteins by using the proteasome inhibitor MG132. While treatment with PF4942847 decreased expression of HSP90 client proteins, adding MG132 inhibited these degradations (Supp. Fig.2B ).
PF4942847 delays tumor growth on HOS-MNNG xenograft model.
We next evaluated the therapeutic potential of PF4942847 in OS xenograft model. Mice bearing OS tumors were orally treated three times per week with 50 mg/kg PF4942847 or with vehicle starting at the day 7. All animals treated with PF4942847 (n=7) exhibited a significant decrease in tumor volume compared with control mice starting at the day 12 (82.6mm 3 and 187.7mm 3 , respectively) and after 34 days (654.3mm 3 and 3148.3mm 3 , respectively; Fig. 2A ). When each animal is considered individually, the incidence of mice progressing with a tumor volume ≥1000mm 3 was significantly diminished by day 23 in PF4942847-treated animals (0/7) compared with controls (7/7, Fig 2B) . Consequently, overall survival was significantly prolonged in the PF4942847-treated group compared with control group (Fig 2C) . Indeed, by day 45, all mice were died or euthanized due to a high tumor burden in the vehicle group, while all mice were still alive in the PF4942847-treated
group. These data demonstrate that targeting HSP90 significantly delays OS tumor growth and prolongs the overall survival in the human HOS-MNNG xenograft model.
Immunohistochemical analysis indicated a decreased Ki67 expression after treatment with PF4942847 (26.8% in PF4942847-groups vs 48.75% in control-group; Fig 2D) . Moreover, significant increase of cleaved-caspase-3 expression as compared to control suggests a PF4942847-induced apoptosis (Fig. 2D) . Overall, inhibition of tumor progression by PF4942847 may result from a combination of decreased proliferative (reduced Ki67 expression) and increased apoptosis (increased cleaved-caspase-3 expression) rates (Fig 2) .
Research. Importantly, no apparent side effects were observed except a non-significant loss of bodyweight, probably due to a small toxicity.
PF4942847 reduced development of pulmonary metastasis by inhibiting invasion, migration and angiogenesis
OS progression is associated with the development of pulmonary metastasis. In our HOS-MMNG model, PF4942847 significantly reduced the incidence of pulmonary metastases in mice (37.5% versus 100% in control) and the number of pulmonary metastasis per mouse (0.87 versus 7.1 metastasis in control; Fig 3A) . Moreover, the HE staining showed vascular emboli in 100% of mice in control group as compared to only 14.3% in treated mice ( Fig   3A) . We also assessed CD146 staining in order to evaluate angiogenesis in tumor tissue.
PF4942847 significantly reduced the number and the development of vessels in tumor ( Fig   3B) . We then examined the effect of PF4942847 on several aspects of tumor cell behavior in vitro. As shown in Fig. 3C , PF4942847 significantly reduced (by 4-fold at 50nM) cells migration and invasion in a dose-dependent manner in HOS-MNNG cells (Fig. 3C ), in accordance with the in vivo results (Fig. 3B ). In addition, zymography assay demonstrated that PF4942847 strongly reduced the activation of matrix metalloproteinase MMP9 in a dosedependent manner without affecting the MMP2 activity in OS cells (Fig. 3D) . Western blot analysis indicated a reduction of C-MET, MMP9 and Focal adhesion kinase (FAK) expressions at protein level in PF4942847-treated cells (Fig. 3D ) without affecting mRNA expressions (Supp Fig.2A ). These decreases of C-MET, FAK and MMP9 expressions at protein level were confirmed in vivo by immunohistochemistry in tumor treated with PF4942847 (Supp. Fig.3 ). All these in vitro and in vivo data demonstrate that targeting HSP90 blocks the formation of lung metastasis.
Effect of PF4942847 on tumor-associated bone lesions
17-AAG has been reported to induce osteoclastogenesis and consequently stimulate tumor progression in bone environment (17, 18). We thus investigated the effect of PF4942847 on the bone micro-architecture of tumor-bearing tibia using micro-computed tomography Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR- volume was reduced after treatment ( Fig. 2A) , PF4942847 failed to significantly prevent the tumor-associated osteolysis as shown by an extensive analysis of bone morphometric parameters of cortical and trabecular bone (Fig. 4A) . However, the increased bone degradation reported in literature with 17-AAG was not reproduced with PF4942847. Indeed, the trabecular bone volume (BV/TV; from 7.3% to 10.5%) and the trabecular number (Tb.N (/mm); from 0.93 to 1.1) were slightly improved after treatment (Fig. 4A) (Fig. 4A ). Histological analysis of the tumor-bearing bone with TRAP staining confirmed that PF4942847 treatment slightly decreased the number of osteoclasts (Fig. 4B ).
We then evaluated the effects of PF4942847 vs. 17-AAG on osteoclast differentiation. 17-AAG increased osteoclast formation as compared to control, while PF4942847 treatment did not (Fig. 4C) . To identify the underlying mechanism of HSP90 inhibitors on osteoclast differentiation, we examined the activation of NF-kB (p-P105) and Src pathways, essential steps for osteoclast differentiation and maturation, in presence of 17-AAG or PF4942847.
While 17-AAG increased p-NF-KB (p-P105) and p-Src expressions, PF4942847 did not change their expressions as compared to control (Fig. 4D) . Consequently, the mRNA expression of NF-kB target gene NFATC1 was increased after 17-AAG but not after PF4942847 treatments, corroborating the osteoclast differentiation results (Fig. 4C) .
All these data demonstrate that PF4942847 does not have any significant effect on osteoclast differentiation and tumor-associated bone lesions, whereas 17-AAG induced osteoclasts formation.
PF4942847 synergistically acts with ZOL to reduce cell proliferation and induce apoptosis in OS cell lines.
Since PF4942847 strongly inhibits tumor progression (Fig. 2) , but does not prevent tumorassociated bone lesions (Fig. 4) , we next evaluated whether the combination of PF4942847
with ZOL prevented tumor-associated osteolysis with a good therapeutic effect on OS tumor growth. The constant ratio design and the combination index (CI) values were performed and calculated according to the Chou and Talalay median effect principal (21). The dose-response curve (combination treatment, PF4942847 and ZOL monotherapy) and the combination index
Research. plots indicate that PF4942847 synergistically acted with ZOL to inhibit tumor cell growth (Fig. 5A) . Then we performed a colony formation assay to evaluate capabilities to recover after 2 days of PF4942847 combined with ZOL. While ZOL did not change the number of colonies, PF4942847 decreased the colony formation compared with control (Fig. 5B) .
However, the combination of PF4942847 with ZOL induced the highest decrease of colony formation compared with each single drug alone (Fig. 5B ).
Flow cytometric analysis shows that apoptotic rates (subG1 fraction) increased significantly when PF4942847 is combined with ZOL (64.8%), compared to control (5.7%), ZOL (8.3%), PF4942847 (34.5%; Fig. 5C ). Moreover, PF4942847+ZOL increased caspase-dependent apoptosis compared to PF4942847 or ZOL monotherapy, as shown by a significant increase of caspase-3 activity, and cleaved-PARP and cleaved-caspase-3 expression (Fig. 5D ).
Reduced cell viability from combined ZOL and HSP90 inhibition may result, in part, from decreased Akt, p-ERK and C-RAF1 expression. Moreover C-MET expression is also reduced in combination therapy (Fig. 5D ).
Combined treatment with PF4942847 and ZOL synergistically delays OS tumor growth, and prevents bone lesions and pulmonary metastasis.
We next assessed the effect in HOS-MNNG model. In order to reduce toxicity and to visualize a synergistic effect of the combined therapy, we used 25mg/kg PF4942847 in this experiment, which corresponds to half-dose of PF4942847 of what was used for the first in vivo experiment (Fig. 2 ). Mice treated with PF4942847+ZOL had significant delays in tumor growth compared with all other groups (Fig. 6A) . Indeed, by day 35, all control mice died or had to be euthanized (tumor volume in the PF4942847+ZOL group was 1090.5mm Fig 6B, left panel) . In addition, PF4942847+ZOL significantly reduced the incidence of pulmonary metastasis in mice (12.5% versus 100% in control, 87.5% in ZOL group and 37.5% in PF4942847 group; Fig 6B) . These data demonstrate that HSP90 inhibition using
Research. Because PF4942847 monotherapy failed to protect bone from tumor-associated lesions (Fig   4) , we next evaluated the combined therapy PF4942847+ZOL on bone parameters of tibia bearing tumors. The combined therapy significantly prevented the cortical bone lesions as shown by increased bone volume (BV=5.07mm
3 ) and bone surface (BS= 79. 01mm 2 ) compared with PF4942847 alone (BV=4.52mm 3 and BS=72.19mm 2 ) or control (BV=4.01mm 3 and BS=67.4mm 2 ). However, the combination was not better compared than ZOL alone (BV=4.96mm 3 and BS=5.07mm 2 ; Fig 6D) . The same results were observed for the trabecular bone volume (BV/TV; from 7% in control to 15.5% after combined therapy, versus 9.9% after PF4942847 treatment and 16% after ZOL treatment) and the trabecular number (Tb.N (/mm); from 0.91mm in control to 1.63mm after combined therapy, versus 1.06mm after PF4942847 treatment and 2.01mm after ZOL treatment; Fig. 6D ). Altogether these data suggest that combined therapy had synergistic effect to delay tumor progression but the prevention of bone lesions is mainly due to the effect of ZOL.
Research. Consequently, the malignancy is maintained with the aid of HSP90 acting on mutated proteins, that become particularly dependent to its activity leading to "HSP90 addiction" for cancer progression and making the cancer cells more susceptible to HSP90 inhibitors than the normal cells (30).
In this study, we examined the effects of the orally bioavailable HSP90 inhibitor, However, the authors only focused on primary tumor often using subcutaneous xenograft models without studying the bone microenvironment and/or pulmonary metastases. Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR- In order to prevent tumor-associated bone lesions, we evaluated the combined therapy of PF4942847 with ZOL. The main aims of drug combination are to achieve synergistic therapeutic effect, dose and toxicity reduction and to minimize or delay the induction of drug resistance (47). Combination studies of HSP90 inhibitors and chemotherapeutic agents or targeted therapies have been previously explored, generally showing either an additive or synergistic effect (23, 48). We here clearly demonstrated that combination of PF4942847 and ZOL synergistically inhibits OS cell proliferation to a greater extent than PF4942847 alone via induction of apoptosis. In vivo, we used a dose of PF4942847 (25mg/kg), which did not have any significant effect on tumor growth in order to reduce a potential toxicity.
PF4942847+ZOL synergistically delayed tumor growth, prolonged the survival and reduced the incidence of metastasis in OS model by reducing proliferation rate and inducing apoptosis. Moreover, the combined therapy significantly prevented tumor-associated bone lesions just as well as ZOL alone, compared to PF4942847 alone or control group. We also confirmed the antitumor activity of ZOL as described (47, 49, 50).
In conclusion, there are many types of targeted therapies, but all share the same characteristic of attempting to capitalize on a biologic characteristic of the cancer cell to eradicate the tumor. This report provides evidence that blocking "HSP90 addiction" in cancer cells may represent a novel therapeutic approach to treat patients with advancedosteosarcoma, by hitting important cancer hallmarks such as cell viability, angiogenesis and metastatic development, with only one drug. Moreover, these data are a proof of principle for the combination of an HSP90 inhibitor with anti-osteoclastic drugs, making this type of treatment as a new potential therapeutic alternative to traditional chemotherapy, by preventing tumor-associated bone lesions and potentially reducing many side effects.
Acknowledgments
This study was supported by l'Association pour la Recherche sur le Cancer (France), and Pfizer Global Research & Development (United States).
Research. Research. 
